11421 Saskatchewan Drive Edmonton, AB, Canada T6G2M9 email@example.com
KMT Hepatech, Inc. provides in vivo research services to companies who are in preclinical development of Hepatitis C (HCV), Hepatitis B (HBV) and Malaria therapeutics and vaccines, utilizing our proprietary platform technology small animal model, the KMT MouseTM.
The KMT MouseTM is a transgenic mouse model with a humanized liver that can be successfully infected with HCV, HBV or malaria and remains infected over extended periods of time. This is the first non-chimpanzee animal model for practical testing of HCV therapies. It is the most advanced in vivo replication model for drug discovery, development and pre-clinical studies.
We enable our clients to efficiently and cost effectively evaluate lead compounds, obtaining statistically and clinically relevant results from a true in vivo setting.
We provide our customers results that are predictive of clinical outcomes observed in humans, as has been established in a series of published validation studies.
KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
January 27 2014
New publications in Xenobiotica on the use of uPA/SCID mouse in toxicity and metabolism studies
January 24 2014
KMT Hepatech to attend International Partnering Conference in Turin, Italy on March 10-12, 2014
December 16 2013
The review "Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies" is published online in Xenobiotica